Agennix AG / Agennix AG to Present at BioEquity Conference processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. 

Martinsried/Munich (Germany), Princeton, NJ and Houston, TX, May 14, 2010 -
Agennix AG (Frankfurt Stock Exchange: AGX) today announced that the Company will
give a corporate presentation at the upcoming BioEquity Europe 2010 conference.
The presentation will be held at 12 PM CET on Thursday, May 20, 2010 in Zurich,
Switzerland.

About Agennix

Agennix AG is a publicly traded biopharmaceutical company that is focused on the
development  of novel  therapies to  improve the  length and  quality of life of
seriously  ill patients in areas of major unmet medical need. The Company's most
advanced  program  is  talactoferrin,  an  oral  therapy  that  has demonstrated
activity  in randomized,  double-blind, placebo-controlled  Phase II  studies in
non-small  cell  lung  cancer,  as  well  as  in severe sepsis. Talactoferrin is
currently  in  Phase  III  clinical  trials  in  non-small cell lung cancer, and
Agennix  plans  to  develop  this  program  further  for the treatment of severe
sepsis. Other clinical development programs include RGB-286638, a multi-targeted
kinase   inhibitor   in   Phase  1 testing;  the  oral  platinum-based  compound
satraplatin;  and a topical gel form  of talactoferrin for diabetic foot ulcers.
Agennix's registered seat is in Heidelberg, Germany. The Company has three sites
of  operation: Martinsried/Munich,  Germany; Princeton,  New Jersey and Houston,
Texas.  For  additional  information,  please  visit  the  Agennix  Web  site at
www.agennix.com.

This  press  release  contains  forward-looking  statements,  which  express the
current  beliefs  and  expectations  of  the  management  of  Agennix  AG.  Such
statements  are  based  on  current  expectations  and  are subject to risks and
uncertainties,  many of  which are  beyond our  control, that could cause future
results,  performance or achievements to  differ significantly from the results,
performance  or  achievements  expressed  or  implied  by  such  forward-looking
statements.  Actual results  could differ  materially depending  on a  number of
factors,   and  we  caution  investors  not  to  place  undue  reliance  on  the
forward-looking  statements  contained  in  this  press release. Forward-looking
statements  speak  only  as  of  the  date  on  which  they are made and Agennix
undertakes no obligation to update these forward-looking statements, even if new
information becomes available in the future.

For           further           information,           please           contact:

Agennix
AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com


In the U.S.: Laurie
Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884

laurie.doyle@agennix.com



Additional media contacts for Europe:
MC Services
AG
Phone: +49 (0) 89 210 228 0

Raimund
Gabriel
raimund.gabriel@mc-services.eu


Hilda
Juhasz
hilda.juhasz@mc-services.eu



Additional investor contact for Europe:
Trout International
LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com 


[HUG#1415942]



 --- End of Message --- 

Agennix AG
Im Neuenheimer Feld 515 Heidelberg Germany

ISIN: DE000A1A6XX4;
Listed: Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;